The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".
Wall Street's median 12-month price target for Beyond Air Inc is $280.00, about 4,528.1% above its August 12 closing price of $6.05.
Quarterly results
U.S. medical device maker's Q1 revenue was flat year over year at $1.8 million.
Net loss widened slightly to $8.15 million from $7.35 million a year earlier.
Q1 loss per share was $11.
Operating loss was -$6.61 million, versus a consensus estimate of from two analysts.
Gross profit was $225,000 and operating expenses were $6.84 million.
Outlook and financing
The company reaffirmed 2026 revenue guidance of $8 million, excluding second-generation LungFit PH system revenue.
It maintained 2027 revenue guidance of $16 million to $18 million, including anticipated LungFit PH revenue.
The company expects FDA approval for the second-generation LungFit PH system in 2H 2026.
Beyond Air completed up to $30.1 million in financing to support commercial expansion.
Drivers behind the quarter
Commercial preparations - The company said it focused on building commercial infrastructure, customer relationships and a sales pipeline ahead of the anticipated LungFit PH system launch.
Distribution expansion - The company expanded its global distribution network for LungFit PH to over 45 countries and signed a new U.S. group purchasing agreement.
Lower R&D spending - The company reported reduced research and development expenses compared with the prior year.
XAIR•
